<VariationArchive VariationID="1408026" VariationName="NM_000069.3(CACNA1S):c.4860dup (p.Val1621fs)" VariationType="Duplication" Accession="VCV001408026" Version="6" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2022-03-28" MostRecentSubmission="2024-04-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1421674" VariationID="1408026">
      <GeneList>
        <Gene Symbol="CACNA1S" FullName="calcium voltage-gated channel subunit alpha1 S" GeneID="779" HGNC_ID="HGNC:1397" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q32.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="201039512" stop="201112426" display_start="201039512" display_stop="201112426" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="201008639" stop="201081693" display_start="201008639" display_stop="201081693" Strand="-" />
          </Location>
          <OMIM>114208</OMIM>
          <Haploinsufficiency last_evaluated="2016-01-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CACNA1S">No evidence available</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-01-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CACNA1S">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000069.3(CACNA1S):c.4860dup (p.Val1621fs)</Name>
      <CanonicalSPDI>NC_000001.11:201043468:GGGGGG:GGGGGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>1q32.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="201043468" stop="201043469" display_start="201043468" display_stop="201043469" variantLength="1" positionVCF="201043468" referenceAlleleVCF="C" alternateAlleleVCF="CG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="201012596" stop="201012597" display_start="201012596" display_stop="201012597" variantLength="1" positionVCF="201012596" referenceAlleleVCF="C" alternateAlleleVCF="CG" />
      </Location>
      <ProteinChange>V1621fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.201012602dup" Assembly="GRCh37">
            <Expression>NC_000001.10:g.201012602dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.201043474dup" Assembly="GRCh38">
            <Expression>NC_000001.11:g.201043474dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009816.2" sequenceAccession="NG_009816" sequenceVersion="2" change="g.74098dup">
            <Expression>NG_009816.2:g.74098dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000069.3" sequenceAccession="NM_000069" sequenceVersion="3" change="c.4860dup" MANESelect="true">
            <Expression>NM_000069.3:c.4860dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000060.2" sequenceAccession="NP_000060" sequenceVersion="2" change="p.Val1621fs">
            <Expression>NP_000060.2:p.Val1621fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="761214441" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000069.3(CACNA1S):c.4860dup (p.Val1621fs) AND multiple conditions" Accession="RCV001909759" Version="3">
        <ClassifiedConditionList TraitSetID="39899">
          <ClassifiedCondition DB="MedGen" ID="C3714580">Hypokalemic periodic paralysis, type 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1866077">Malignant hyperthermia, susceptibility to, 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-05-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000069.3(CACNA1S):c.4860dup (p.Val1621fs) AND not provided" Accession="RCV003487285" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-10-29" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000069.3(CACNA1S):c.4860dup (p.Val1621fs) AND Malignant hyperthermia, susceptibility to, 5" Accession="RCV004010845" Version="2">
        <ClassifiedConditionList TraitSetID="5783">
          <ClassifiedCondition DB="MedGen" ID="C1866077">Malignant hyperthermia, susceptibility to, 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-24" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-02-24" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2022-03-28" MostRecentSubmission="2024-04-20">
        <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
        <Description>Conflicting classifications of pathogenicity</Description>
        <Explanation DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(2)</Explanation>
        <Citation Type="general">
          <ID Source="PubMed">26247046</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28012042</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34608571</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34777470</ID>
        </Citation>
        <Comment DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(2)</Comment>
        <DescriptionHistory Dated="2023-03-04">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="39899" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2383" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HypoPP</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hypokalemic periodic paralysis, type 1</ElementValue>
                <XRef ID="MONDO:0042979" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HOKPP1</ElementValue>
                <XRef Type="MIM" ID="170400" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hypokalemic periodic paralysis (hypoPP) is a condition in which affected individuals may experience paralytic episodes with concomitant hypokalemia (serum potassium &lt;3.5 mmol/L). The paralytic attacks are characterized by decreased muscle tone (flaccidity) more marked proximally than distally with normal to decreased deep tendon reflexes. The episodes develop over minutes to hours and last several minutes to several days with spontaneous recovery. Some individuals have only one episode in a lifetime; more commonly, crises occur repeatedly: daily, weekly, monthly, or less often. The major triggering factors are cessation of effort following strenuous exercise and carbohydrate-rich evening meals. Additional triggers can include cold, stress/excitement/fear, salt intake, prolonged immobility, use of glucosteroids or alcohol, and anesthetic procedures. The age of onset of the first attack ranges from two to 30 years; the duration of paralytic episodes ranges from one to 72 hours with an average of nearly 24 hours. Long-lasting interictal muscle weakness may occur in some affected individuals and in some stages of the disease and in myopathic muscle changes. A myopathy may occur independent of paralytic symptoms and may be the sole manifestation of hypoPP.</Attribute>
                <XRef ID="NBK1338" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301512</ID>
                <ID Source="BookShelf">NBK1338</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2010">
                <ID Source="PubMed">20298421</ID>
              </Citation>
              <XRef ID="681" DB="Orphanet" />
              <XRef ID="C3714580" DB="MedGen" />
              <XRef ID="MONDO:0042979" DB="MONDO" />
              <XRef Type="MIM" ID="170400" DB="OMIM" />
            </Trait>
            <Trait ID="5445" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Malignant hyperpyrexia susceptibility type 5</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant hyperthermia, susceptibility to, 5</ElementValue>
                <XRef ID="MONDO:0011163" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant hyperthermia susceptibility type 5</ElementValue>
                <XRef ID="Malignant+hyperthermia+susceptibility+type+5/4430" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MHS5</ElementValue>
                <XRef ID="GTR000557682" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="601887" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Pharmacogenetic</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are precipitated by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine). The triggering substances cause uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase (CK) concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure. In nearly all cases, the first manifestations of MH (tachycardia and tachypnea) occur in the operating room; however, MH may also occur in the early postoperative period. There is mounting evidence that some individuals with MHS will also develop MH with exercise and/or on exposure to hot environments. Without proper and prompt treatment with dantrolene sodium, mortality is extremely high.</Attribute>
                <XRef ID="NBK1146" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3367" />
                <XRef ID="3367" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMHG, 2018">
                <ID Source="PubMed">33131754</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301325</ID>
                <ID Source="BookShelf">NBK1146</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_MalignantHyperthermia-enPro649.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Malignant hyperthermia</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Malignant-Hyperthermia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, RYR1 and CACNA1S Pathogenic Variants (Malignant Hyperthermia), 2019</CitationText>
              </Citation>
              <XRef ID="423" DB="Orphanet" />
              <XRef ID="C1866077" DB="MedGen" />
              <XRef ID="MONDO:0011163" DB="MONDO" />
              <XRef Type="MIM" ID="601887" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="5783" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5445" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Malignant hyperpyrexia susceptibility type 5</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant hyperthermia, susceptibility to, 5</ElementValue>
                <XRef ID="MONDO:0011163" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant hyperthermia susceptibility type 5</ElementValue>
                <XRef ID="Malignant+hyperthermia+susceptibility+type+5/4430" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MHS5</ElementValue>
                <XRef ID="GTR000557682" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="601887" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Pharmacogenetic</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are precipitated by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine). The triggering substances cause uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase (CK) concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure. In nearly all cases, the first manifestations of MH (tachycardia and tachypnea) occur in the operating room; however, MH may also occur in the early postoperative period. There is mounting evidence that some individuals with MHS will also develop MH with exercise and/or on exposure to hot environments. Without proper and prompt treatment with dantrolene sodium, mortality is extremely high.</Attribute>
                <XRef ID="NBK1146" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3367" />
                <XRef ID="3367" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMHG, 2018">
                <ID Source="PubMed">33131754</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301325</ID>
                <ID Source="BookShelf">NBK1146</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_MalignantHyperthermia-enPro649.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Malignant hyperthermia</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Malignant-Hyperthermia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, RYR1 and CACNA1S Pathogenic Variants (Malignant Hyperthermia), 2019</CitationText>
              </Citation>
              <XRef ID="423" DB="Orphanet" />
              <XRef ID="C1866077" DB="MedGen" />
              <XRef ID="MONDO:0011163" DB="MONDO" />
              <XRef Type="MIM" ID="601887" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7135379" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="12a0a98ff5b16e809bf32989aeed41d159ad1a9a9de6a25e771e23c081c33719|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003828843" DateUpdated="2024-02-04" DateCreated="2023-03-04" Type="SCV" Version="2" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000069.3:c.4860dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12922107</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4203481" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="889661|MedGen:C3714580;C2930984" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002186900" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-05-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26247046</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28012042</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with CACNA1S-related conditions. This variant is present in population databases (rs775883314, ExAC 0.01%). This sequence change creates a premature translational stop signal (p.Val1621Argfs*12) in the CACNA1S gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CACNA1S are known to be pathogenic (PMID: 26247046, 28012042).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CACNA1S" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.201012596_201012597insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3714580" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2930984" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9005171" SubmissionDate="2024-04-16" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="429386|MONDO:0011163" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004815887" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="All of Us Research Program, National Institutes of Health" OrgID="509529" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain Significance</GermlineClassification>
          <Citation>
            <ID Source="PubMed">28012042</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34608571</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34777470</ID>
          </Citation>
          <Comment>This pathogenicity assessment is for autosomal dominant malignant hyperthermia susceptibility phenotype. This frameshift variant is predicted to result in an absent or nonfunctional CACNA1S protein product. Loss of CACNA1S gene function due to truncation and splice variants is thought to cause congenital myopathy and hypokalemic periodic paralysis (PMID: 28012042, 34608571, 34777470). However, the role of such loss-of-function variants in autosomal dominant malignant hyperthermia susceptibility is not clearly understood. Therefore, this variant is classified as a Variant of Uncertain Significance.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>108544</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CACNA1S" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.201012597dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0011163" />
          </Trait>
        </TraitSet>
        <Comment>This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB14382316</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4203481" TraitType="Disease" MappingType="XRef" MappingValue="C2930984" MappingRef="MedGen">
        <MedGen CUI="C1866077" Name="Malignant hyperthermia, susceptibility to, 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7135379" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4203481" TraitType="Disease" MappingType="XRef" MappingValue="C3714580" MappingRef="MedGen">
        <MedGen CUI="C3714580" Name="Hypokalemic periodic paralysis, type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9005171" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0011163" MappingRef="MONDO">
        <MedGen CUI="C1866077" Name="Malignant hyperthermia, susceptibility to, 5" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

